Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
84.7 EUR | +6.41% | +6.61% | +40.70% |
Apr. 02 | Spain's Rovi Obtains US FDA Approval for Marketing Risvan as Schizophrenia Treatment | MT |
Mar. 12 | Rovi, Partners to Form Entity for Advanced Therapies R&D | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+40.70% | 4.7B | |
+24.17% | 556B | |
-6.33% | 354B | |
+19.90% | 331B | |
+7.95% | 296B | |
+13.45% | 233B | |
+6.04% | 201B | |
-10.51% | 193B | |
-12.26% | 143B | |
-6.47% | 144B |
- Stock Market
- Equities
- ROVI Stock
- News Laboratorios Farmaceuticos Rovi, S.A.
- Laboratorios Farmaceuticos Rovi S A : Rovi To Upgrade Spanish Facility To Boost Moderna's COVID-19 Vaccine Production